How certain is the benefit after prostate treatment?
PFMT is used in continence rehabilitation after prostate surgery, but comparative evidence is less settled than for female stress incontinence. Published reviews do not establish a guaranteed recovery time or one universally effective programme.
This page checks the public Cochrane, EAU and NICE sources on 9 October 2026. It focuses on urinary continence, not on cancer treatment or a promise of sexual-function recovery.
What the 2023 Cochrane review actually compared
The Cochrane review searched studies through 22 April 2022 and included 25 trials with 3079 men who had incontinence after prostate surgery. Twenty-three trials concerned radical prostatectomy; just one concerned transurethral resection, and one did not specify the operation.
Its key comparisons included PFMT with biofeedback and combinations of conservative treatments against no treatment, sham treatment or written/verbal instructions. In the combined-treatment comparison, participant-reported cure or improvement at six to twelve months differed little, with low-certainty evidence. Quality-of-life results also showed little difference, with moderate certainty.
For PFMT plus biofeedback, subjective and objective cure findings did not point consistently in the same direction and had low certainty. Several key outcomes were unreported. The review identified no electrical- or magnetic-stimulation study reporting its key outcomes for the selected comparison.
These results concern particular comparisons and protocols. They do not establish that every PFMT approach is ineffective, that a different dose would work, or that an app would reproduce a trial intervention. Protocol variation, small studies and incomplete adverse-event reporting limit the conclusions.
Surgery type and timing matter
A review dominated by radical prostatectomy cannot provide the same answer for radiotherapy, benign-prostate procedures or every surgical technique. Baseline leakage, catheter status, instruction and the recovery interval need to be matched to the actual treatment.
Continence can change during postoperative recovery even without the studied intervention. Improvement from your own starting point therefore cannot by itself identify how much benefit an exercise programme caused. A diary of leakage and pad use can still help the treating team judge your progress and burden; it is not a diagnostic test.
Why specialist rehabilitation remains appropriate
EAU’s prostate-cancer quality-of-life guidance lists conservative continence options while acknowledging uncertainty about effectiveness. Its rehabilitation recommendation covers individual goals and the wider effects of cancer treatment.
NICE NG131, recommendation 1.3.39, calls for access to specialist continence assessment and conservative treatment for troublesome urinary symptoms after prostate-cancer treatment. Persistent severe symptoms have additional specialist pathways. A recommendation to offer care is different from a quantified guarantee for PFMT alone.
Using PelvicEx without overriding the surgical plan
Follow your surgical team’s instructions about exercise, catheter use and healing. Do not choose a start date or progress to harder contractions from this evidence review. PelvicEx can time permitted practice but cannot inspect healing, identify the leakage mechanism, verify technique or monitor a catheter.
Ask for reassessment when leakage worsens, emptying becomes difficult, pain appears or recovery does not follow the agreed plan. Seek urgent care for sudden inability to urinate, major bleeding, severe rapidly escalating pain, fever with marked illness, or new saddle/genital numbness with acute bladder, bowel or leg changes. An average research finding never overrides these warning signs.
Related guides
Continue with when to start after prostatectomy, preoperative pelvic-floor training and continence recovery times.
Sources
- Johnson EE et al. Conservative interventions for managing urinary incontinence after prostate surgery. Cochrane, 2023. DOI: 10.1002/14651858.CD014799.pub2. Review.
- EAU. Prostate cancer guideline: Quality of life outcomes, current online edition checked 9 October 2026.
- NICE. Prostate cancer: diagnosis and management, NG131. Recommendations 1.3.39–1.3.40.